Inspire Medical price target lowered to $150 from $180 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Inspire Medical (INSP) to $150 from $180 and keeps an Outperform rating on the shares as part of a broader research note on MedTech ahead of Q3 results. There is broad interest in the Medical Supplies & Devices sector, with multiple opportunities across the landscape and attractive valuations with dislocations creating opportunities, the analyst tells investors in a research note. Sentiment for Inspire remains lackluster headed into earnings however due to lowered 2025 revenue guidance calling for 10% y/y growth during Q2-Q4, Q3 being another transition quarter for Inspire V ramp, uncertainty around GLP-1 impact, and expectations for conservative initial guide for 2026 both on revenue and margins, the firm added.